Thromb Haemost 2011; 106(05): 868-876
DOI: 10.1160/TH11-05-0358
Consensus Document
Schattauer GmbH

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.

A consensus document of the Italian Federation of Thrombosis Centers (FCSA)

Authors

  • Vittorio Pengo

    1   Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy
  • Luciano Crippa

    2   Thrombosis Research Unit, IRCCS H S.Raffaele, Milan, Italy
  • Anna Falanga

    3   Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy
  • Guido Finazzi

    4   Division of Hematology, Ospedali Riuniti, Bergamo, Italy
  • Francesco Marongiu

    5   Department of Medical Sciences, University Hospital, Cagliari, Italy
  • Gualtiero Palareti

    6   Department of Angiology and Blood Coagulation ″Marino Golinelli″, University Hospital, Bologna, Italy
  • Daniela Poli

    7   Department of Heart and Vessels, Thrombosis Center, Careggi University Hospital, Firenze, Italy
  • Sophie Testa

    8   Thrombosis Centre, District Hospital, Cremona, Italy
  • Eros Tiraferri

    9   Haemostasis and Thrombosis Centre, City Hospital, Rimini, Italy
  • Alberto Tosetto

    10   Department of Hematology, San Bortolo Hospital, Vicenza, Italy
  • Armando Tripodi

    11   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Maggiore Hospital Foundation and Università degli Studi di Milano, Milan, Italy
  • Cesare Manotti

    12   Anticoagulation Service, Fidenza, Italy
Further Information

Publication History

Received: 27 May 2011

Accepted after major revision: 19 August 2011

Publication Date:
23 November 2017 (online)

Preview

Summary

Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.